← Leaderboards
Anthony John O'Donoghue
University Of California, San Diego
$3,220,387
Attributed
$6,014,524
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,014,524 · 7
By mechanism
R01$3,242,175 · 1
R21$2,772,349 · 6
Top collaborators
- Lars Eckmann7 shared
- Conor Caffrey3 shared
- Drew Alexander Hall3 shared
- Shawn C Owen2 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Warren G Lewis$4,910,991
- Shawn C Owen$536,647
- Michelle Arkin$14,172,629
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsResistancePeptidesPharmaceutical PreparationsDesignMulticatalytic Endopeptidase ComplexProteasome InhibitorPeptide HydrolasesParasitesInfectionChemistrySubstrate SpecificityCytotoxicityLibrariesPharmaceutical ChemistryDrug ResistanceToxic EffectParasitic DiseasesLeadDrug DevelopmentNew Therapeutic TargetProteinsParasitologyCell Line
Grant awards (17)
Proteasome inhibitors against mucosal protozoan pathogens$648,435
R01 · FY2025 · AI
New tools to facilitate drug discovery for pathogen proteasomes$438,500
R21 · FY2025 · AI · contact PI
Proteasome inhibitors against mucosal protozoan pathogens$648,435
R01 · FY2024 · AI
Proteasome inhibitors against mucosal protozoan pathogens$648,435
R01 · FY2023 · AI
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis$197,500
R21 · FY2023 · AI
Tumor-specific drug activation by pericellular proteases$177,630
R21 · FY2023 · CA · contact PI
Proteasome inhibitors against mucosal protozoan pathogens$648,435
R01 · FY2022 · AI
The catalytic core of the proteasome as a drug target to treat Human African Trypanosomiasis$237,000
R21 · FY2022 · AI
Tumor-specific drug activation by pericellular proteases$231,823
R21 · FY2022 · CA · contact PI
Proteasome inhibitors against mucosal protozoan pathogens$648,435
R01 · FY2021 · AI
Point-of-Care Quantitation of Sputum Neutrophil Elastase Activity in Chronic Airway Disease$197,396
R21 · FY2021 · EB · contact PI
Selective proteasome inhibitors for trichomoniasis$196,875
R21 · FY2020 · AI
Point-of-Care Quantitation of Sputum Neutrophil Elastase Activity in Chronic Airway Disease$196,875
R21 · FY2020 · EB · contact PI
Selective proteasome inhibitors for trichomoniasis$236,250
R21 · FY2019 · AI
Point-of-Care Quantitation of Sputum Neutrophil Elastase Activity in Chronic Airway Disease$236,250
R21 · FY2019 · EB · contact PI
Exploring the proteasome as a new drug target to treat schistosomiasis$193,750
R21 · FY2018 · AI · contact PI
Exploring the proteasome as a new drug target to treat schistosomiasis$232,500
R21 · FY2017 · AI · contact PI